Table 2.
Study population participants |
NCSP-R∫ |
|||
---|---|---|---|---|
n | % | N (Jan-Jun 2009) | % | |
Age groups |
|
|
|
|
20-24 |
148 |
24.9 |
514 |
22.9 |
25-29 |
136 |
22.9 |
479 |
21.4 |
30-34 |
92 |
15.5 |
348 |
15.5 |
35-39 |
79 |
13.3 |
279 |
12.4 |
40-44 |
52 |
8.8 |
179 |
8.0 |
45-49 |
34 |
5.7 |
165 |
7.4 |
50-54 |
25 |
4.2 |
102 |
4.6 |
55-59 |
17 |
2.9 |
69 |
3.1 |
60-64 |
7 |
1.2 |
73 |
3.3 |
65-69 |
4 |
0.7 |
34 |
1.5 |
Ethnicity groups |
|
|
|
|
European/Other |
466 |
78.5 |
1678 |
74.9 |
Maori |
98 |
16.5 |
367 |
16.4 |
Asian |
16 |
2.7 |
127 |
5.7 |
Pacific |
14 |
2.4 |
70 |
3.1 |
Total | 594 | 100 | 2242 | 100 |
* The New Zealand NSCP-R contains cervical cytology results for all women in New Zealand, with the exception of those who choose to opt-off . For the study, and on the NCSP-R, a high grade cytology report includes women with a reported cytology result of either high grade squamous intra-epithelial lesion (HSIL), atypical squamous cells, cannot rule out a high grade lesion (ASC-H), atypical glandular cells(AGC), adenocarcinoma in situ (AIS) or cytology suggestive of invasive cancer (SC, AC1-AC5).
∫ Screened women with high grade cytology as reported in New Zealand for the period 1st January-30th June 2009[15].